UMLS:C0043167 - FACTA Search

Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Target Concepts:

Query: UMLS:C0043167 (pertussis)
19,595 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Children with sickle cell anemia are more exposed to infection than healthy children. Indeed, infections are the major cause of morbidity and mortality in children with sickle cell anemia, especially those aged 6 months to 5 years. Phagocytosis is reduced in these children. Polynuclear neutrophils reveal various poorly understood irregularities and are associated with a reduction of phagocytic power: zinc deficiency, reduced post-phagocytic oxidative metabolism, and a prevalence of neutrophils not forming red sheep-like globule carriers of immunoglobulin H. The power of the antibody which renders germs susceptible to phagocytosis in the serum is reduced in sickle cell patients. This may be tied to a disorder in the alternate complementary route with reduction of C3 and properdin. Sequestration of sickle cell-shaped red blood cells, splenic congestion, and short circuits of important functional territories contribute to spleen dysfunction, which occurs early. Common pathogens attacking sickle cell patients are pneumococci, salmonella species, and Haemophilus influenzae. They cause very grave infections (e.g., septicemia and purulent meningitis). Prevention of infections dwells on three perspectives: early screening for sickle cell anemia and for spleen dysfunction, preventive penicillin therapy, and vaccination. In Benin, vaccination is the only means to prevent infections. Essential vaccinations for children with sickle cell anemia include BCG, diphtheria-pertussis-tetanus, polio, and Rouvax. Strongly recommended vaccinations are Pneumovax 23, HEVAC B, TAB, vaccine against H. influenzae, and vaccine against mumps. A vaccine calendar for children with sickle cell anemia guides health workers when they must administer the vaccines and their boosters over a six year period. It is not yet universal in health facilities in Benin. A short- and long-term evaluation of the calendar's efficacy would allow one to appreciate its real impact on reducing morbidity and mortality in children with sickle cell anemia.
...
PMID:[Prevention of infectious diseases in the drepanocytic child]. 1229 Jan 82

The decreasing tendency in incidence of infectious diseases observed in Poland in previous years as compared with 2000 has weakened or stopped. Increase in the incidence of selected infectious diseases can be linked with the improvement of surveillance resulting from the better diagnostics and greater attention paid to these diseases (including borreliosis, salmonella, and Haemophilus influenzae meningitis). Between 1999 and 2000, the most intense decrease in the number of mumps, measles, and scarlet fever cases as an effect of the end of epidemics was observed. At the same time increase in the number of pertussis, rubella, chickenpox, and meningitis cases was noticed. In 2000, the first case of human rabies since 1986 has been reported. In 2000, compared with 1999, among all notified deaths percentage of deaths attributed to infectious diseases (0.83%) and infectious diseases death rate (0.79 per 10,000) were slightly higher and were the highest in the last decade. As in 1999 the observed increase was effect of the influenza deaths increase (358 deaths, mortality 0.022%). The main disease causing the largest number of deaths, as in previous years, was tuberculosis (36.5% of total infectious diseases deaths).
...
PMID:[Infectious diseases in Poland in 2000]. 1237 53

In most countries, pertussis surveillance is inadequate for accurately estimating numbers of cases or deaths. Good estimates are needed to help set priorities for vaccination programmes. We aimed to develop a simple, reliable, and explicit method for estimating pertussis cases and deaths for children under 15 years to calculate the global disease burden in 1999. We estimated the proportion of susceptible children becoming infected in countries with poor vaccination coverage (<70%) in 1999 at 30% by 1 year, 80% by 5 years, and 100% by 15 years of age and for countries with good coverage (> or =70%) at 10% by 1 year, 60% by 5 years, and 100% by 15 years. Vaccine efficacy was estimated at 80% for preventing infection and 95% for preventing deaths. We used UN population estimates and vaccination coverage reported to WHO (adjusted for specific survey data if available). Case fatality ratios for countries with high and low child mortality were derived from published and unpublished work. For some countries with good vital events registration we used reported deaths adjusted for underascertainment. In 1999 there were an estimated 48.5 million pertussis cases in children worldwide. Deaths from pertussis were estimated at 390000 and at 295000 after adjustment for local data sources. Based on this approach, disability-adjusted life years from pertussis (12.7 million) in 2000 exceeded those of other preventable diseases such as lung cancer (11.4 million) and meningitis (5.8 million). This simple approach yields estimates that can be used for setting vaccination programme priorities. Better data are needed on the public health importance of pertussis in high mortality countries, the benefits of incomplete vaccination, and the harm from delayed vaccination.
...
PMID:How best to estimate the global burden of pertussis? 1283 46

Vaccination of infants with conjugated Haemophilus influenzae type b (Hib) vaccines has been proven to reduce Hib meningitis by 95% and pneumoniae by 20%. The routine use of Hib vaccine is facilitated by the introduction of combination vaccines into the EPI (Expanded Plan of Immunization). The objective of this study was to compare the immunogenicity and reactogenicity of an extemporaneously mixed DTPw/Hib (diphtheria-tetanus-whole cell pertussis) combination, using the technology of two Brazilian manufacturers, against a licensed DTPw/Hib European combination in 108 infants vaccinated at 2, 4 and 6 months according to the local national schedule. The Brazilian combination was highly immunogenic with Hib seroprotection rates (anti-PRP > 0.15 mg /ml of 98% after 2 doses and 100% after 3). Also for tetanus and pertussis the new Brazilian combination was as immunogenic as the European counterpart, except the diphtheria seroprotection rates and titers were lower. There was also no clinically relevant difference in reactogenicity. If these feasibility results are confirmed, the Brazilian DTPw/Hib combination should help to boost the uptake of Hib vaccination in Brazil.
...
PMID:Feasibility study of the immunogenicity and safety of a novel DTPw/Hib (PRP-T) Brazilian combination compared to a licensed vaccine in healthy children at 2, 4, and 6 months of age. 1290 31

The article presents the state of variola epidemiology as well as the effects of this highly infectious disease in Poland in the nineteenth and the twentieth centuries, in the context of developing vaccination programs, which eventually led to the eradication of variola. Additionally, the progress in research on vaccines and vaccinations, as well as increase in vaccine production, led to the eradication of poliomyelitis in Europe (2002), in both Americas (1994), and in the Eastern Pacific area. Drawing on the close examination of the state of epidemiology in relation to all infectious diseases, the article suggests revisions in the annual vaccination programs, which pill cause decrease in such diseases as pertussis, meningitis, mumps, morbilli and rubeola.
...
PMID:[Directions of changes in the Polish Vaccination Programs]. 1292 Oct

Infant mortality in Hungary was higher than in other European countries; however, the reported incidence of sudden infant death syndrome (SIDS) has been lower than those for Western Europe and the United States. Childhood immunisation has been reported to be a protective factor for SIDS. In Britain, the change to an earlier immunisation schedule for diphtheria, pertussis, and tetanus appeared to be associated with a shift in the age distribution of SIDS. In 1999, immunisation for Haemophilus influenzae type b (Hib) was introduced for Hungarian infants at the age of 2 months. Data for total infant mortality and SIDS in Hungary were analysed between 1990 and 2002. Infection was the major cause of death among Hungarian infants followed by SIDS. Following introduction of Hib immunisation, there was a decrease in deaths due to meningitis from an average of 3.5% of all infant deaths between 1990 and 1998 to an average of 1% of all infant deaths between 1999 and 2002 (p=0.00). There was also a significant decrease in the proportion of SIDS in the age range > or =2 months from 48% in the earlier period to 39% after introduction of the vaccine (p=0.03). The decrease in SIDS might be due in part to decrease in unrecognised Hib infections or to induction of antibodies by the tetanus toxoid to which the Hib polysaccharide is conjugated that are cross reactive with bacterial toxins implicated in SIDS.
...
PMID:Change in immunisation schedule and sudden infant death syndrome in Hungary. 1532 4

Vaccines are a key contributor to public health, especially in developing countries. Despite numerous demonstrations of the cost-effectiveness of immunisation, vaccines spending accounted for only 1.7% of the total pharmaceutical market in 2002, when UNICEF estimated that 34 million children were not reached by routine immunisation, most of them in developing countries. Several international organizations or initiatives, like the Global Alliance for Vaccines and Immunisation (GAVI), have defined a long-term goal of universal immunisation in developing countries. There is an urgent need to estimate the financial resources required to meet this goal. The objective of this study was to anticipate the funding needs for childhood immunisation in developing countries over the 2004-2014 period. The study scope includes all the 75 countries eligible for support from GAVI, and covers existing vaccines that are considered as a priority for GAVI (DTP (diphtheria, tetanus, pertussis), hepatitis B, Haemophilus influenzae type b (as a stand alone presentation or in combination with DTP) and yellow fever) as well as future vaccines (meningitis A and C, rotavirus, human papilloma virus (HPV), malaria, Streptococcus pneumoniae and tuberculosis) likely to be available within the 10-year period. We developed a methodology to estimate the number of doses required, based on disease prevalence and incidence, target populations, introduction dates of new vaccines, coverage dynamics and dosing regimen. The introduction price and price evolution of vaccines over time were modelled, taking into account the type of vaccine, the expected return on investment from vaccine manufacturers and the competitive landscape. Non-vaccine costs (capital costs and non-vaccine recurrent costs) were estimated based on the number of people immunised and number of doses dispensed, using available case studies as a reference. According to the optimal scenario that would consider the provision of all vaccines to all relevant developing countries as soon as they are available, funding requirements to cover the associated total costs over the 10-year period were estimated to be about US$ 30 billion. Vaccines-related costs represent the largest share, with estimated costs of US$ 21 billion (among which 18 billion for new vaccines), the remaining needs being split between capital costs and other recurrent costs. Accounting for the main imponderables (such as delay in vaccines launch compared to industry plans) as well as probable phasing of vaccine introduction in countries, the total costs of immunisation would be reduced to US$ 14-17 billion over the same period. Vaccines-related costs represent the largest share (US$ 7.1-9.3 billion, among which 4.3-6.5 billion for new vaccines). This study advocates for the anticipation of the substantial financial resources needed to (a) purchase and introduce these vaccines in the developing countries in order to reduce the time lag between availability in industrialised and developing countries; and (b) stimulate vaccine researchers and manufacturers to continue research and development of much needed vaccines for the developing world.
...
PMID:Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective. 1597 69

In May 1991 a decree supplementing the federal Epidemic Law concerning the mandatory notification of communicable diseases was implemented by the Ministry of Health in Saxony-Anhalt. This was updated and newly implemented in 1997. With implementation of the national Protection against Infection Act in 2001 further amendment of the state regulation (published in April 2005) be came necessary. The following diseases or laboratory evidence of the underlying pathogens, respectively, will now be notifiable with inclusion of the affected individual's name: aseptic meningitis, mumps, rubella, varicella, epidemickera to conjunctivitis, pertussis, and pneumococcal meningitis. The possibility of preventing further spread of the pathogen to others though immediate implementation of preventive measures by the public health service justifies notification of the individual's name. Furthermore, the epidemiological situation is to be monitored and evaluated. This also applies to Lyme disease, which will be anonymously notifiable. Particular emphasis is placed on vaccine-preventable diseases in the state regulation for mandatory notification in Saxony-Anhalt, since priority is placed on attaining the health goal "age-appropriate vaccination status in over 90% of the population". The state-specific notification regulation of Saxony-Anhalt has worked well in preventing and controlling communicable diseases. It is a source of reliable data, which may be helpful in the discussion regarding the amendment of the Protection against Infection Act. Non-anonymous notification should be enforced nationally at least for all vaccine-preventable diseases for which a post-exposure vaccination is recommended by the Standing Committee on Vaccination (STIKO).
...
PMID:[Complementary to notification required by the national Protection against Infection Act. State-specific mandatory infectious disease notification in Saxony-Anhalt]. 1616 Aug 86

Two hundred forty-one healthy infants were enrolled in an open randomised controlled study of three doses of DTaP-IPV-Hib (Group 1) or DTwP/Hib+OPV (Group 2) at 2, 3 and 4 months of age given concurrently with a meningitis C conjugate vaccine. After each dose, local reactions (any grade) were less common in Group 1 than Group 2 (p<0.03). Axillary temperature >37.5 degrees C, decreased feeding, reduced activity, irritability and crying in the week after vaccination were also less common in Group 1 than Group 2 (p<0.05 for each symptom, all doses combined). Severe local reactions and systemic symptoms were uncommon and occurred equally in both groups. The pentavalent DTaP-IPV-Hib vaccine was less reactogenic than the quadrivalent DTwP-Hib vaccine, as expected when changing from whole cell pertussis (wP) to an acellular pertussis (aP) component.
...
PMID:A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. 1651 34

In Senegal, the Expanded Programme of Immunization started by 1986 as a routine programme targeting 7 diseases: tuberculosis, tetanus, diphtheria, pertussis, poliomyelitis, measles and recently yellow fever Immunization against hepatitis B and Haemophilus influenzae b are proposed since 2005, but not implemented yet. In addition, there are mass immunization campaigns, such as National Immunization Day organized every year since 1999 against poliomyelitis and, in case of outbreak, against meningitis or yellow fever. In a 30,000 inhabitants rural study zone, vaccine contacts of children under 15 years of age are updated regularly several times a year since 1984. We also performed yearly cross sectional surveys from 1999 to estimate vaccine coverage in children of 24 months of age. Immunization status was assessed by vaccination cards presented by the children's parents and registers of health centres. We compared the results from both longitudinal and cross sectional surveys, which showed some differences. The last method seemed to indicate higher immunization rates. The vaccine coverage was slightly but not significantly higher in the study zone compared to the general vaccine coverage in Senegal, excepted for measles immunization for which the coverage was significantly lower in Niakhar. However results showed that interventions of all types lead to a high vaccine coverage (up to 80%) but are not sustainable. In the intervals, vaccine coverage decreased dramatically (below 40%), due mainly to irregular supply of antigens and poor accessibility of health facilities. Other factors are mentioned.
...
PMID:[Analysis of evolution of vaccine coverage in Niakhar, a rural area of Senegal, between 1984 and 2003]. 1725 59

<< Previous 1 2 3 4 5 6 7 8 Next >>